Previous 10 | Next 10 |
SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that its BioJet™ Systemic Oral Delivery Platform has met key performance milestones as part of its research collaboration...
2023-12-22 17:35:50 ET More on Biora Therapeutics Biora Therapeutics, Inc. (BIOR) Q3 2023 Earnings Call Transcript FDA clears Biora to begin Phase 1 testing of ulcerative colitis treatment Biora submits updated IND application to FDA for BT-600 Seeking Alpha&...
SAN DIEGO, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it received an Issue Notification from the U.S. Patent and Trademark Office for a patent related to the treatment of gastro...
Transaction results in nearly 60% reduction in net debt and brings $16.7 million in new capital for the company Demonstrates investor confidence in near-term catalysts for NaviCap™ and BioJet™ platforms SAN DIEGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics,...
SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced a new research collaboration with a large pharmaceutical company for its BioJet™ Systemic Oral Delivery Platform. The new...
2023-12-04 08:20:01 ET Losers: Neximmune ( NEXI ) -36% . Garden Stage Limited Ordinary Shares ( GSIW ) -31% . ShiftPixy ( PIXY ) -17% . Harbor Custom Development ( HCDI ) -13% . Alaska Air Group ( ALK ) -12% follow global marke...
2023-12-01 09:58:28 ET DENVER, Colo., Dec. 1, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; NLS Pharmaceutics Ltd (NASDAQ: NLSP), Biora Therapeutics Inc, (NASDAQ: BIOR), NexImmune Inc (NASDAQ: NEXI), Ha...
2023-11-30 17:10:39 ET More on Biora Therapeutics Biora Therapeutics, Inc. (BIOR) Q3 2023 Earnings Call Transcript Biora submits updated IND application to FDA for BT-600 Biora IND for BT-600 delayed due to FDA request for more info Seeking Alpha’s Qua...
BT-600 will deliver a proprietary liquid formulation of tofacitinib via the NaviCap™ device for topical delivery to the colon SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, tod...
2023-11-13 21:04:02 ET Biora Therapeutics, Inc. (BIOR) Q3 2023 Earnings Conference Call November 13, 2023, 16:30 ET Company Participants Chuck Pedala - LifeSci Advisors Adi Mohanty - CEO Eric d'Esparbes - CFO Conference Call Participants Joe Pantginis...
News, Short Squeeze, Breakout and More Instantly...
Biora Therapeutics Inc. Company Name:
BIOR Stock Symbol:
NASDAQ Market:
Biora Therapeutics Inc. Website:
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired Data modeling suggests tofacitinib tissue concentrations greater than IC90 through at least 16 hours after dosing SAN DIEGO, July 18...
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be held on Wednesday, July 17, 2024. The event will feature Bruce Sands, MD, MS (Icahn School of ...
Drug-device combination leverages Biora’s NaviCap ™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ab...